Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 3:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Idiopathic Intracranial Hypertension
Interventions: Acetazolamide, Optic Nerve Sheath Fenestration, Ventriculoperitoneal CSF Shunting; Drug · Procedure
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years to 63 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 33
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 26 more

Conditions: Hypertension
Interventions: aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 641 participants
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Pulmonary Hypertension, Pulmonary Vascular Disease, Left Heart Disease
Interventions: Transthoracic Echocardiography (TTE), Lung ultrasound; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hypertension, Type 2 Diabetes
Interventions: Home visit; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypertension
Interventions: Experimental: Pharmacist-Bidirectional Texting Group, Active Comparator: Control Group; Other
Lead sponsor: Linnea Polgreen; Other
Eligibility: 21 Years to 100 Years
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Pulmonary Hypertension, Mitral Valve Disease
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Chicago, Illinois • Durham, North Carolina

Conditions: Hypertension
Interventions: Self-Paced Programmed Instruction (SPPI), Home Blood Pressure Monitor, Usual Care, Printed Materials; Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 21 Years to 80 Years
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Uncontrolled Hypertension
Interventions: RTN-001, Matching placebo control; Drug
Lead sponsor: Retension Pharmaceuticals. Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 44
States / cities: Alexander City, Alabama • Birmingham, Alabama • Glendale, Arizona + 39 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Nanodropper adaptor, control; Device
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Hypertension Complicating Pregnancy (Diagnosis), Preeclampsia
Interventions: Labetalol Hydrocholoride 200 mg orally every 12 hours, Nifedipine 60 mg orally daily, Atenolol 25 mg daily; Drug
Lead sponsor: University of Tennessee Medical Center; Other
Eligibility: 18 Years to 51 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Hypertension
Interventions: Lumbar spine surgery, Neurologic/neuropsychometric examinations; Procedure · Other
Lead sponsor: Columbia University; Other
Eligibility: 60 Years to 90 Years
Enrollment: 179 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma, Glaucoma, Suspect
Interventions: Standard GAT, Fixed force GAT, Upright applanating prototype, Pneumotonometer; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes Mellitus, Type 2, Hypertension, Vitamin D Deficiency
Interventions: Blood draw; Diagnostic Test
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 25 Years to 80 Years
Enrollment: 40 participants
Timeline: 2017 – 2026
U.S. locations: 2
States / cities: St Louis, Missouri

Conditions: Hypertension
Interventions: Nebivolol, Valsartan, Nebivolol/valsartan combination; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Salt Sensitivity of Blood Pressure, High Blood Pressure, Inflammation, Renin-Angiotensin-Aldosterone System
Interventions: 2-hydroxybenzylamine, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypertension
Interventions: BP-ICAN; Device
Lead sponsor: Southcentral Foundation; Other
Eligibility: 18 Years and older · Male only
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Anchorage, Alaska • Wasilla, Alaska

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Pilocarpine, Ofloxacin, Prednisolone; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 30 Years to 100 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Hypertension
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Netarsudil Ophthalmic Solution 0.02%; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 22
States / cities: Huntington Beach, California • Laguna Hills, California • Petaluma, California + 18 more

Conditions: Preeclampsia
Interventions: ACOG education pamphlet on preeclampsia, Preeclampsia education tool; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension, Type 2 Diabetes Mellitus (T2DM)
Interventions: Coach-Directed Tailored DASH Groceries Plus Lifestyle Intervention, Self-Shopping DASH diet advice; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Systemic Sclerosis, Pulmonary; Hypertension
Interventions: Dimethyl Fumarate (DMF), Placebo Oral Tablet; Drug
Lead sponsor: Robert Lafyatis; Other
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 4
States / cities: Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Supine Hypertension, Autonomic Failure
Interventions: Tilt, Elevated trunk, Tilt - In home, Elevated Trunk - In home; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetes, Dyslipidemia, Hypertension, Coronary Atherosclerosis
Interventions: Counseling, Interactive Education, Group Support, Pharmacologic case management; Behavioral · Procedure
Lead sponsor: Providence VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Providence, Rhode Island

Search by objective public record fields.

Surgical Idiopathic Intracranial Hypertension Treatment Trial

A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure

Pulmonary Hypertension in Left Heart Disease

Assessing the Efficacy of Targeted Home Visits in the Management of Chronic Conditions

A Pharmacist Intervention for Monitoring and Treating Hypertension Using Bidirectional Texting

Symptomatic Pulmonary Arterial Hypertension After Mitral Valve Surgery

Behavioral Study to Control Blood Pressure

A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension

Use of Nanodropper vs. Standard Eyedropper in Patients With Glaucoma and Ocular Hypertension

Impedance Cardiography to Decrease the Risk of Preeclampsia

Cognitive Dysfunction in Hypertensive Patients Having Spine Surgery

Automated Applanation Tonometry - Updated

Vitamin D and Immune Mechanisms of Hypertension in Type 2 Diabetics

24 Hour Ambulatory Cardiac Oxygen Consumption

Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans

Blood Pressure-Improving Control Among Alaska Native People" (BP-ICAN)

Pilocarpine After Combined Cataract/Trabectome Surgery

Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

Improving Patient Understanding of Preeclampsia

Groceries Plus Multi-Component Lifestyle Intervention for Adults With Hypertension and Type 2 Diabetes

Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

Effect of Raised Head of the Bed on Lying Blood Pressure in Autonomic Failure

Strategies to Maintain Cardiac Risk Control After Discharge From Cardiovascular Risk Reduction Clinic